-DOCSTART- -X- O
We -X- _ O
designed -X- _ O
and -X- _ O
produced -X- _ O
a -X- _ O
self-assembling -X- _ B-Intervention
protein -X- _ I-Intervention
nanoparticle. -X- _ I-Intervention
This -X- _ O
self-assembling -X- _ B-Intervention
protein -X- _ I-Intervention
nanoparticle -X- _ I-Intervention
contains -X- _ I-Intervention
five -X- _ I-Intervention
CD8 -X- _ I-Intervention
( -X- _ I-Intervention
+ -X- _ I-Intervention
) -X- _ I-Intervention
HLA-A03-11 -X- _ I-Intervention
supertypes-restricted -X- _ I-Intervention
epitopes -X- _ I-Intervention
from -X- _ O
antigens -X- _ O
expressed -X- _ O
during -X- _ O
Toxoplasma -X- _ B-Patient
gondii’s -X- _ O
lifecycle -X- _ O
, -X- _ O
the -X- _ O
universal -X- _ O
CD4 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cell -X- _ O
epitope -X- _ O
PADRE -X- _ O
, -X- _ O
and -X- _ O
flagellin -X- _ O
as -X- _ O
a -X- _ O
scaffold -X- _ O
and -X- _ O
TLR5 -X- _ O
agonist. -X- _ O
These -X- _ O
CD8 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cell -X- _ O
epitopes -X- _ O
were -X- _ O
separated -X- _ O
by -X- _ O
N -X- _ O
/ -X- _ O
KAAA -X- _ O
spacers -X- _ O
and -X- _ O
optimized -X- _ O
for -X- _ O
proteasomal -X- _ O
cleavage. -X- _ O
Self-assembling -X- _ B-Intervention
protein -X- _ I-Intervention
nanoparticle -X- _ I-Intervention
adjuvanted -X- _ I-Intervention
with -X- _ I-Intervention
TLR4 -X- _ I-Intervention
ligand-emulsion -X- _ I-Intervention
GLA-SE -X- _ I-Intervention
were -X- _ O
evaluated -X- _ O
for -X- _ O
their -X- _ O
efficacy -X- _ O
in -X- _ O
inducing -X- _ O
IFN-γ -X- _ O
responses -X- _ O
and -X- _ O
protection -X- _ O
of -X- _ O
HLA-A*1101 -X- _ B-Patient
transgenic -X- _ I-Patient
mice -X- _ I-Patient
against -X- _ I-Patient
T. -X- _ I-Patient
gondii. -X- _ I-Patient
Immunization -X- _ O
, -X- _ O
using -X- _ O
self-assembling -X- _ B-Outcome
protein -X- _ I-Outcome
nanoparticle-GLA-SE -X- _ I-Outcome
, -X- _ I-Outcome
activated -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
to -X- _ I-Outcome
produce -X- _ I-Outcome
IFN-γ. -X- _ I-Outcome
Self- -X- _ I-Outcome
assembling -X- _ I-Outcome
protein -X- _ I-Outcome
nanoparticle-GLA-SE -X- _ I-Outcome
also -X- _ I-Outcome
protected -X- _ I-Outcome
HLA-A*1101 -X- _ I-Outcome
transgenic -X- _ I-Outcome
mice -X- _ I-Outcome
against -X- _ I-Outcome
subsequent -X- _ I-Outcome
challenge -X- _ I-Outcome
with -X- _ I-Outcome
Type -X- _ I-Outcome
II -X- _ I-Outcome
parasites. -X- _ I-Outcome
Hence -X- _ O
, -X- _ O
combining -X- _ B-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cell-eliciting -X- _ I-Outcome
peptides -X- _ I-Outcome
and -X- _ I-Outcome
PADRE -X- _ I-Outcome
into -X- _ I-Outcome
a -X- _ I-Outcome
multi-epitope -X- _ I-Outcome
protein -X- _ I-Outcome
that -X- _ I-Outcome
forms -X- _ I-Outcome
a -X- _ I-Outcome
nanoparticle -X- _ I-Outcome
, -X- _ I-Outcome
administered -X- _ I-Outcome
with -X- _ I-Outcome
GLA-SE -X- _ I-Outcome
, -X- _ I-Outcome
leads -X- _ I-Outcome
to -X- _ I-Outcome
efficient -X- _ I-Outcome
presentation -X- _ I-Outcome
by -X- _ I-Outcome
major -X- _ I-Outcome
histocompatibility -X- _ I-Outcome
complex -X- _ I-Outcome
Class -X- _ I-Outcome
I -X- _ I-Outcome
and -X- _ I-Outcome
II -X- _ I-Outcome
molecules. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
these -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
activation -X- _ O
of -X- _ O
TLR4 -X- _ O
and -X- _ O
TLR5 -X- _ O
could -X- _ O
be -X- _ O
useful -X- _ O
for -X- _ O
development -X- _ O
of -X- _ O
vaccines -X- _ O
that -X- _ O
elicit -X- _ O
T -X- _ O
cells -X- _ O
to -X- _ O
prevent -X- _ O
toxoplasmosis -X- _ O
in -X- _ O
humans -X- _ O
. -X- _ O

